ClinicalTrials.gg
RecruitingNCT05450718Updated Jul 21, 2026

Low-dose Buprenorphine Initiation for Opioid Use Disorder

A Phase 4 interventional study of buprenorphine-naloxone and buprenorphine-naloxone in Opioid Use Disorder, sponsored by Montefiore Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Montefiore Medical Center · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Opioid-Related Disorders by Montefiore Medical Center — 3 open to participants now, 3 under way, 1 of them phase 3. Opioid-Related Disorders · Montefiore Medical Center.

Planned enrollment
3rd of 10
70 · median 27
Started
2024
with 1 other
Phase 4
2 of 10
1 open now
Registered
5th of 10
by date

Among the 10 studies in Opioid-Related Disorders by Montefiore Medical Center, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2024, is one of 2 in phase 4, and was the 5th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

3 of the 10 studies in Opioid-Related Disorders by Montefiore Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Opioid-Related Disorders by Montefiore Medical Center, or all of them as a file.
02

Study summary

The purpose of this study is to test whether low-dose buprenorphine initiation for treatment of opioid use disorder is safe and effective.

Read the detailed description

After being informed about the study and potential risks, all participants will be given written informed consent. Eligible participants will be randomized in a 1:1 ratio to an 8-day low-dose buprenorphine initiation protocol or treatment as usual, and conduct study visits at baseline and weeks 2 and 4. The investigators will also provide participants with mobile phones to collect real-time data on withdrawal, anxiety, craving and substance use through electronic Ecological Momentary Assessment (EMA) technology.

03

Conditions studied

  • Opioid Use Disorder

Keywords

  • micro-induction
  • microdosing
  • low-dose initiation
  • buprenorphine
  • micro-initiation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Any gender, aged 18 years or greater
  4. Opioid Use Disorder (based on Diagnostic and Statistical Manual- Version 5 criteria)
  5. Ability to take sublingual medication
  6. Willingness to adhere to the assigned buprenorphine initiation regimen
  7. Fluency in English or Spanish
  8. For participants of : agreement to use highly effective during study participation

Exclusion criteria

Exclusion Criteria:

  1. Use of FDA-approved medications for opioid use disorder treatment (within 7 days prior to screening), including methadone, buprenorphine, or naltrexone
  2. Diagnosis of Alcohol Use Disorder, severe or Benzodiazepine Use Disorder, severe (based on Diagnostic and Statistical Manual- Version 5 criteria)
  3. Severe untreated mental illness, meaning psychosis or suicidality
  4. Presence of an acute or chronic medical condition that would make participation medically hazardous
  5. Pregnancy or lactation
  6. Known allergic reactions to buprenorphine or naloxone
  7. Inability to consent due to cognitive impairment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Low-dose initiation

    Participants randomized to low-dose buprenorphine initiation will start low-dose buprenorphine-naloxone (bup-nx) according to an at-home, 8-day protocol (below). Participants in the low-dose buprenorphine initiation arm will be allowed to continue taking the full opioid agonist that they were taking at the time of enrollment until they reach a therapeutic dose of buprenorphine-naloxone. Day 1: 0.5 mg once; Day 2: 0.5 mg every 12 hours; Day 3: 1 mg every 12 hours; Day 4: 2 mg every 12 hours; Day 5: 3mg every 12 hours; Day 6: 4 mg every 12 hours; Day 7: 6 mg every 12 hours; Day 8: 8 mg every 12 hours

    Drug: buprenorphine-naloxone

  • Active comparator
    Treatment as usual

    Participants randomized to treatment as usual will start buprenorphine-naloxone (bup-nx) following standard clinical guidelines for two-day, at-home initiation.

    Drug: buprenorphine-naloxone

Interventions

  • Drugbuprenorphine-naloxone

    Low-dose initiation of buprenorphine-naloxone protocol

    Also known as: buprenorphine microdosing, buprenorphine micro-induction, buprenorphine micro-initiation

  • Drugbuprenorphine-naloxone

    Standard clinical guidelines for a two-day buprenorphine-naloxone initiation

06

What researchers measure

Primary outcomes

  1. Recruitment Feasibility: Percentage of subjects assessed who enroll in the clinical trial.

    This pilot study is designed to establish the feasibility of a future, full-powered clinical trial. The primary question this study seeks to answer is whether primary care patients with opioid use disorder are willing to enroll in a clinical trial of low-dose inductions. The study will aim to enroll 25% of subjects who are assessed. "Assessed" is defined as having been referred to the study staff. Enrollment is defined as having been randomized to a treatment arm.

    Time frame: At baseline study visit (time zero)

Secondary outcomes

  1. Protocol Feasibility: Proportion of participants who follow adequate fidelity to the low-dose initiation study protocol.

    This pilot study will seek to answer whether participants of a clinical trial adhere to a low-dose buprenorphine-naloxone (bup-nx) initiation protocol. The study aims to achieve 80% of study participants meeting adequate fidelity to the low-dose study protocol. Adequate fidelity is defined as meeting all of the following: 1. First dose is a low dose (defined as less than 1-.25mg bup-nx) (yes/no), 2. Daily bup-nx dose equivalent to assigned daily dose: For the first 7 days the reported total daily bup-nx dose is within the prespecified assigned daily dose limit, 3. Variability: Each day's daily dose is increased from the prior daily dose (within daily limits) (yes/no). Measured using once daily participant self-report through mobile data collection technology.

    Time frame: From baseline to day 8

  2. Number of participants who uptake buprenorphine treatment at 2 weeks

    Uptake is defined as having a positive urine drug test (UDT) for buprenorphine at the 2-week study visit (dichotomous, yes/no).

    Time frame: 2-week study visit

  3. Number of participants retained in buprenorphine treatment at 6 weeks

    6-week retention is defined as having an active buprenorphine prescription and buprenorphine-positive UDT at the 6-week visit

    Time frame: 6-week study visit

  4. Non-prescribed opioid use

    The mean number of days of non-prescribed opioid use, defined as self-reported use of heroin, fentanyl, or non-prescribed opioid analgesics in the prior 14 days using an adapted version of the Addiction Severity Index. Will be reported for each arm at the 6-week visit (continuous).

    Time frame: From baseline to 6-week study visit

  5. Withdrawal severity

    Measured using the Subjective Opioid Withdrawal Score, a 16-item scale based on symptom severity (from 0=Not at all, to 4=extremely). Multilevel mixed-linear effects models will be used to assess between arms.

    Time frame: From baseline to 2-week study visit

  6. Precipitated withdrawal

    The percentage of participants who experience precipitated withdrawal during the first 2 weeks of initiation. Defined as withdrawal symptoms that get markedly worse within 90 minutes of taking buprenorphine-naloxone dose. Markedly worse will be defined as a change in 10 points on Subjective Opioid Withdrawal Score (SOWS) severity, or as determined by a study clinician. SOWS is a 16-item scale based on symptom severity (from 0=Not at all, to 4=extremely, yielding a possible overall range from 0-64). Precipitated withdrawal is expected only during periods of increasing buprenorphine-naloxone dose titrations: for the low-dose protocol precipitated withdrawal could occur from dose 1 - 13; for the treatment as usual protocol precipitated withdrawal could occur from dose 1 - 5. SOWS will be collected 5 times/day using daily mobile data collection entries.

    Time frame: From baseline to 2-week study visit

  7. Mild vs Mod-Severe Withdrawal symptoms

    The proportion of severe vs mild-moderate buprenorphine-related withdrawal events between study arms will be assessed using the using the Subjective Opioid Withdrawal Score, a 16-item scale based on symptom severity (from 0=Not at all, to 4=extremely). The 16 items are summed with a score of 1-10 representing mild withdrawal, 11-20 as moderate withdrawal, and \>/= 21 as severe withdrawal.

    Time frame: From baseline to 2-week study visit

Other outcomes

  1. Changes in severity of withdrawal scores during buprenorphine initiation buprenorphine initiation

    Using multilevel mixed-linear effects models to examine effects within individuals (level 1), and between study arms (level 2) of Subjective Opioid Withdrawal Score, 16-items scaled on symptom severity (scale from 0=Not at all to 4=extremely) scored as mild, mod, and severe withdrawal. Data collected using daily mobile data collection technology entries.

    Time frame: From baseline to 2-week study visit

  2. Changes in severity of anxiety scores during buprenorphine initiation

    Using multilevel mixed-linear effects models to examine effects within individuals (level 1), and between study arms (level 2) of Generalized Anxiety Disorder-7 scale, 7-items scaled on symptom frequency (scale from 0=Not at all to 3=Nearly every day), scored from minimal to severe anxiety. Data collected using daily mobile data collection technology entries.

    Time frame: From baseline to 2-week study visit

  3. Changes in severity of cravings scores during buprenorphine initiation

    Using multilevel mixed-linear effects models to examine effects within individuals (level 1), and between study arms (level 2). Measured using two Visual Analog Scale items asking about current cravings and cravings in the past 1-hour, scaled 0-100 on from 0=None at all to 100=Extreme cravings. The score is an average of the results of the two questions. Data collected using daily mobile data collection technology entries.

    Time frame: From baseline to 2-week study visit

  4. Non-prescribed opioid use during buprenorphine initiation

    The mean number of days of non-prescribed opioid use throughout the buprenorphine initiation period. Measured by participant self-report through daily mobile data collection technology entries.

    Time frame: baseline to 2-week study visit

  5. Fentanyl exposure after buprenorphine initiation

    The percent of participants exposed to fentanyl on point of care urine fentanyl test at the 2-week study visit.

    Time frame: baseline to 2-week study visit

  6. Non-fatal opioid overdose since last study visit

    The mean number of non-fatal overdose events. Self-reported measure at the 2-week and 6-week study visits.

    Time frame: baseline to 6-week study visit

  7. Strict Protocol Fidelity

    Proportion of participants of the low-dose initiation arm who meet criteria for strict adherence to the buprenorphine-naloxone (bup-nx) protocol. Defined as having both the correct bup-nx dose (mg) and correct timing each day of the initiation protocol: 1. Correct block dose (mg) (yes/no): A reported dose is within the assigned dose limit for specified time block. 2. Correct time block (yes/no): A reported dose is within the specified time block for all doses for the first 7 days (doses 1- 13; excluding day 8 doses 14, 15). Measured using once daily participant self-report through daily mobile data collection technology entries.

    Time frame: baseline- day 7

  8. Proportional fidelity

    Specified time blocks with correct dose and timing / Total number of time blocks in the protocol

    Time frame: baseline- day 7

  9. Provider time-burden

    Measured as the total time per visit for clinical visits during the study period (continuous). Variable extracted from provider notes in the electronic medical record.

    Time frame: 8 days

  10. Proportion of doses of buprenorphine taken according to treatment as usual arm initiation protocol

    Measured using once daily participant self-report through Ecological Momentary Assessment technology and defined as the proportion of pre-packaged doses taken each day during the initiation protocol.

    Time frame: baseline to day 2

  11. Withdrawal symptoms at 1 week

    Proportion of mild vs moderate-severe withdrawal scores at one week. Defined as the Subjective Opioid Withdrawal Score (SOWS) at the 1-week visit. SOWS is a 16-items scaled on symptom severity, with participants reporting whether they have each symptom (0=Not at all to 4=extremely). The 16 items are summed with a score of 1-10 representing mild withdrawal, 11-20 as moderate withdrawal, and \>/= 21 as severe withdrawal. SOWS will be collected at a 1-week phone call visit.

    Time frame: day 7

  12. Opioid cravings over 1st week of buprenorphine initiation

    Measured using the Obsessive Compulsive Drug Use Scale (OCDUS). The OCDUS an 11 item instrument measuring cravings over 1 week, each item scored on a 5-point Likert scale 0= No craving to 5= Most intense craving, with anchors at each whole interval number, total score calculated by averaging the scores on the 11 items. OCDUS is administered at the 1-week phone call visit.

    Time frame: day 0-7

  13. Anxiety severity at 1 week

    Measured using the 4-item Patient-Reported Outcomes Measurement (PROMIS) 4a anxiety instrument, each item scaled from 1=Never to 5=Always. The total score is the total additive value of all 4 items, which is then translated into a T-score for each participant using a supplied table. The T-score rescales the raw score into a standardized T-score with a mean of 50 and a standard deviation (SD) of 10. Instrument is administered at the 1-week phone call visit.

    Time frame: day 7

  14. Mild vs Mod-Severe Withdrawal symptoms

    The percentage of severe vs mild-moderate buprenorphine-related withdrawal events between study arms will be assessed using the using the Subjective Opioid Withdrawal Score, a 16-item scale based on symptom severity (from 0=Not at all, to 4=extremely). The 16 items are summed with a score of 1-10 representing mild withdrawal, 11-20 as moderate withdrawal, and \>/= 21 as severe withdrawal.

    Time frame: baseline to 2-week visit

  15. Buprenorphine treatment uptake, clinical visit

    Defined as having a positive urine drug test (UDT) for buprenorphine at either a 2-week clinical visit, as per electronic medical record, or research visit (yes/no). Missing either outcome (2-week UDT) will be considered as 'no uptake' (failed initiation).

    Time frame: 2-week visit

  16. First buprenorphine-naloxone (bup-nx) dose

    The dose (mg) of the first bup-nx taken during the initiation process (continuous). Self-reported through mobile data collection technology.

    Time frame: Day 0-1

  17. Buprenorphine-naloxone (bup-nx) Dose per day

    The total bup-nx dose (mg) for each day of the initiation protocol (continuous). Self-reported through mobile data collection technology.

    Time frame: Baseline - day 8

  18. Buprenorphine-naloxone (bup-nx) Dose variability

    The change in bup-nx dose (mg) between each day of the protocol (continuous). Self-reported through mobile data collection technology.

    Time frame: Baseline - day 8

  19. Continued use of full-agonist opioid during initiation protocol (yes/no)

    Self-reported opioid use will be collected daily using mobile data collection technology.

    Time frame: Baseline - day 8

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Hayes BT, Sabado A, Minami H, Zhang C, Holm M, Khalid L, Lu TY, Torres-Lockhart K, Fox AD. MiBUP: A pilot randomized controlled trial of low-dose initiation of buprenorphine for opioid use disorder: Design and rationale. Contemp Clin Trials Commun. 2026 Jan 5;49:101594. doi: 10.1016/j.conctc.2026.101594. eCollection 2026 Feb. PubMed 41567709 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 3 months to 5 years following article publication

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.

Of 48 non-industry phase 4 interventional studies under Opioid-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's planned 28 months is below that.

Counting every sponsor, half of 52 studies reached it within 32 months; a quarter within 20 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2022
First posted
Jul 11, 2022
StartActual
Nov 11, 2024
Primary completionEst.
Mar 17, 2027
CompletionEst.
Jun 30, 2027
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05450718
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
Nov 11, 2024
Primary completion
Mar 17, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 21, 2026

Study contacts

Benjamin T Hayes, MD, MS, MPH
Contact
bhayes@montefiore.org
4156700850
Benjamin T Hayes, MD, MS, MPH
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion